VSIG4 and rheumatoid arthritis: In an acidic environment, the platform delivers CRIg-CD59 to the affected site of RA and can inhibit complement activation and repair VSIg4+ macrophage barrier function, while targeting osteoclasts to inhibit their differentiation [32].